July 8, 2014 | After signing a $500 million agreement with pharmaceutical company Bayer HealthCare last year, Compugen announced that it received its first payment of $1.2 million for reaching a cancer immunotherapy milestone. The $1.2 million is only a fraction of the nearly $30 million in milestone payments that Comupgen is set to receive from Bayer. The collaboration between Compugen and Bayer is aimed at developing and commercializing therapeutic antibodies originally discovered by Compugen.
Compugen was founded in 1993 by Eli Mintz, Simchon Faigler, and Amir Natan as a drug discovery company, but also engages in the development and marketing of bioinformatics software platforms.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023

EU Awards $5M To Greenhouse Solar Panel Project
February 07, 2023

Israel Builds Super-Advanced Children’s Hospital
February 07, 2023

Two Thirds Of Hi-Tech Workers In Israel Are Men, Study Finds
February 06, 2023
Facebook comments